Clinical characteristics of 53 NPM1mut patients at diagnosis (n = 53)
| Variable . | No. . | % . |
|---|---|---|
| Age, years | ||
| Median | 51 | |
| Range | 24-66 | |
| Sex | ||
| Female | 26 | 49 |
| Male | 27 | 51 |
| AML history | ||
| De novo | 51 | 96 |
| t-AML | 2 | 4 |
| Cytogenetics (banding analysis) | ||
| Normal karyotype | 44 | 83 |
| Deletion 9q | 4 | 8 |
| Not available | 5 | 9 |
| NPM1 mutation type | ||
| A | 40 | 75 |
| B | 5 | 9 |
| D | 4 | 8 |
| Other | 4 | 8 |
| WBC count, ×109/L | ||
| Median | 23 | |
| Range | 1-253 | |
| BM blasts, % | ||
| Median | 90 | |
| Range | 22-100 | |
| Induction cycles, n | ||
| 1 | 12 | 23 |
| 2 | 41 | 77 |
| Remission status after first induction cycle (n = 53) | ||
| CR | 38 | 72 |
| PR | 14 | 26 |
| RD | 1 | 2 |
| Remission status after second induction cycle (n = 41) | ||
| CR | 40 | 98 |
| Relapse | 1 | 2 |
| Consolidation therapy (n = 52) | ||
| High-dose Cytarabin | 44 | 83 |
| Allogeneic SCT | 4 | 8 |
| Autologous SCT | 4 | 8 |
| CIR, months | ||
| Median | 8.8 | |
| Range | 1.3-110.5 | |
| Overall survival after diagnosis, months | ||
| Median | 17.3 | |
| Overall survival after relapse, months | ||
| Median | 7.3 | |
| Variable . | No. . | % . |
|---|---|---|
| Age, years | ||
| Median | 51 | |
| Range | 24-66 | |
| Sex | ||
| Female | 26 | 49 |
| Male | 27 | 51 |
| AML history | ||
| De novo | 51 | 96 |
| t-AML | 2 | 4 |
| Cytogenetics (banding analysis) | ||
| Normal karyotype | 44 | 83 |
| Deletion 9q | 4 | 8 |
| Not available | 5 | 9 |
| NPM1 mutation type | ||
| A | 40 | 75 |
| B | 5 | 9 |
| D | 4 | 8 |
| Other | 4 | 8 |
| WBC count, ×109/L | ||
| Median | 23 | |
| Range | 1-253 | |
| BM blasts, % | ||
| Median | 90 | |
| Range | 22-100 | |
| Induction cycles, n | ||
| 1 | 12 | 23 |
| 2 | 41 | 77 |
| Remission status after first induction cycle (n = 53) | ||
| CR | 38 | 72 |
| PR | 14 | 26 |
| RD | 1 | 2 |
| Remission status after second induction cycle (n = 41) | ||
| CR | 40 | 98 |
| Relapse | 1 | 2 |
| Consolidation therapy (n = 52) | ||
| High-dose Cytarabin | 44 | 83 |
| Allogeneic SCT | 4 | 8 |
| Autologous SCT | 4 | 8 |
| CIR, months | ||
| Median | 8.8 | |
| Range | 1.3-110.5 | |
| Overall survival after diagnosis, months | ||
| Median | 17.3 | |
| Overall survival after relapse, months | ||
| Median | 7.3 | |
WBC, white blood cell; BM, bone marrow; SCT, stem cell transplantation; PR, partial remission; RD, refractory disease; CIR, cumulative incidence of relapse.